NR1D2 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-03. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
== External links == Ohmefentanyl at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Yaoxue Xuebao Yaoxue Xuebao (ISSN:0513-4870) is a monthly peer-reviewed scopus-indexed journal from 1960, from 1962 to 1966, from 1979 to Present.
The integrity of a modern cold chain is maintained by a suite of interconnected technologies that provide real-time monitoring, data logging, and operational control. These systems are a key part of fleet digitalization and are essential for ensuring product safety, regulatory compliance, and operational efficiency. The development of advanced frameworks for temperature monitoring, leveraging IoT platforms, has become a key area of innovation in logistics.
Between 1970 and 1998, the number of different types of breakfast cereals in the United States more than doubled, from about 160 to around 340; as of 2012, there were roughly 5,000 different types (estimate based on the mass customization of online shopping). In this highly competitive market, cereal companies have developed an ever-increasing number of varieties and flavors (some are flavored like dessert or candy). Although many plain wheat-, oat- and corn-based cereals exist, a great many other varieties are highly sweetened, and some brands include freeze-dried fruit as a sweet element. The breakfast cereal industry has gross profit margins of 40–45%, In 2009, market researchers expected the market to grow at a CAGR of 7.4% (in the next 5 years); it has had steady and continued growth throughout its history.
Type II civilizations could use the same techniques as a Type I civilization, but applied to a large number of planets in a large number of star systems. A Dyson sphere or Dyson swarm and similar constructs are hypothetical megastructures originally described by Freeman Dyson as a system of orbiting solar power satellites designed to completely encircle a star and capture most or all of its energy output. Another means of generating usable energy would be to feed a stellar mass into a black hole, and collect the photons emitted by the accretion disk. A less exotic means would be to simply capture photons already escaping from the accretion disk, thereby reducing a black hole's angular momentum; this is known as the Penrose process. However, this may only be possible for a Type III civilization. Star lifting is a process by which an advanced civilization could remove a substantial portion of a star's matter in a controlled manner for other uses. Antimatter is likely to be produced as an industrial byproduct of a number of megascale engineering processes (such as the aforementioned star lifting), and could therefore be recycled. In multiple star systems with a sufficiently large number of stars: absorbing a small but significant fraction of the output of each individual star. Stellar engines can be used to move stars.
Sources: en.wikipedia.org
Drugs are also used to inhibit enzymes needed for the survival of pathogens. For example, bacteria are surrounded by a thick cell wall made of a net-like polymer called peptidoglycan. Many antibiotics such as penicillin and vancomycin inhibit the enzymes that produce and then cross-link the strands of this polymer together. This causes the cell wall to lose strength and the bacteria to burst. In the figure, a molecule of penicillin (shown in a ball-and-stick form) is shown bound to its target, the transpeptidase from the bacteria Streptomyces R61 (the protein is shown as a ribbon diagram). Antibiotic drug design is facilitated when an enzyme that is essential to the pathogen's survival is absent or very different in humans. Humans do not make peptidoglycan, therefore antibiotics that inhibit this process are selectively toxic to bacteria. Selective toxicity is also produced in antibiotics by exploiting differences in the structure of the ribosomes in bacteria, or how they make fatty acids.
=== Pharmacokinetics === The oral bioavailability of cannabidiol is approximately 6% in fasting state and 36.5–57.3% in fed-state in humans, while its bioavailability via inhalation is 11–45% (mean 31%). The oral bioavailability of cannabidiol varies based on several factors such as formulation, dose, and food intake. The sublingual bioavailability of cannabidiol is approximately 12–35%. The elimination half-life of cannabidiol in blood is 56–61 hours after oral doses twice per day over 7 days. Based on the pharmacokinetic analysis of long-term dosing of cannabidiol in humans, the terminal elimination half-life is estimated to be >134 hours. Cannabidiol is metabolized in the liver as well as in the intestines by cytochrome P450 enzymes.
=== Woodhouse Sixth Form College === Daisy Edgar-Jones, actress Johann Hari, journalist and writer Julia Hartley-Brewer, journalist, broadcaster and presenter Naomie Harris, actress David Hirsh, sociologist Jesse Honey, Mastermind winner 2010 and World Quiz Champion 2012 Michael McIntyre, stand-up comedian Ali Jawad, Paralympic powerlifter (silver medallist, Rio 2016) Robert Rinder, known as "Judge Rinder", barrister and television personality Stephen Bush, journalist Antigoni Buxton, Love Island participant and singer
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.